

ARMSTRONG ERNEST
Form SC 13D/A
June 18, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

BIOGENTECH CORP.

(Name of Issuer)
COMMON STOCK

(Title of Class of Securities)

09063N 10 4

(CUSIP Number)

CHASLAV RADOVICH, 2445 MCCABE WAY, SUITE 150, IRVINE, CA 92614
(949) 757-0001

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

JUNE 15, 2004

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. []

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: ARMSTRONG ERNEST - Form SC 13D/A

1

CUSIP No. 09063N 10 4

	1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Ernest Armstrong	
	2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b)	
	3.	SEC Use Only	
	4.	Source of Funds (See Instructions)	OO
	5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
	6.	Citizenship or Place of Organization	U.S.
Number of	7.	Sole Voting Power	125,814 -----
Shares			
Beneficially	8.	Shared Voting Power	2,020,000 -----
Owned by			
Each	9.	Sole Dispositive Power	125,814 -----
Reporting			
Person	10.	Shared Dispositive Power	2,020,000 -----
With			
	11.	Aggregate Amount Beneficially Owned by Each Reporting Person	2,145,814
	12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
	13.	Percent of Class Represented by Amount in Row (11)	8.8% -----
	14.	Type of Reporting Person (See Instructions)	

IN

2

Edgar Filing: ARMSTRONG ERNEST - Form SC 13D/A

ITEM 1. SECURITY AND ISSUER

This statement relates to shares of the common stock, \$.001 par value of Biogenetech Corp., a Nevada corporation (the "Issuer"). The principal executive offices of the Issuer are located at 2445 McCabe Way, Suite 150, Irvine, CA 92614.

ITEM 2. IDENTITY AND BACKGROUND

- (a) Name: Ernest Armstrong
- (b) Business Address: 2445 McCabe Way, Suite 150,
Irvine, CA 92614
- (c) Present Principal Occupation: Vice President of the Issuer.
- (d) Disclosure of Criminal Proceedings: none
- (e) Disclosure of Civil Proceedings: none
- (f) Citizenship: U.S.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

Ernest Armstrong, acquired 25,814 shares of the Issuer's shares pursuant to an S-8 filed on April 29, 2004 in lieu of employee wages to be paid him by the Issuer. This transaction results in Mr. Armstrong owning 125,814 shares of the Issuer's common stock directly and personally, and 2,020,000 shares as managing member and majority owner of Gene Pharmaceuticals, LLC.

ITEM 4. PURPOSE OF TRANSACTION

Ernest Armstrong, acquired 25,814 shares of the Issuer's shares pursuant to an S-8 filed on April 29, 2004 in lieu of employee wages to be paid him by the Issuer. Mr. Armstrong owns 125,814 shares of the Issuer's common stock directly and personally, and 2,020,000 shares as managing member and majority owner of Gene Pharmaceuticals, LLC.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

Mr. Armstrong beneficially owns a total of 2,145,814 shares of the Issuer's common stock as follows:

(a) Ernest Armstrong, sole officer and director of the Issuer, owns 125,814 shares individually, which comprises 0.5% of the Issuer's outstanding common stock, and 2,020,000 shares as sole owner of Gene Pharmaceuticals, LLC. Gene Pharmaceuticals, LLC directly owns 2,020,000 shares of the Issuer's common stock which comprises 8.3% of the Issuer's total issued and outstanding shares.

(b) Ernest Armstrong has sole voting and dispositive power as to the 125,814 shares he owns individually and as to the 2,020,000 shares which he controls as managing member and majority owner of Gene Pharmaceuticals, LLC.

Edgar Filing: ARMSTRONG ERNEST - Form SC 13D/A

(c) None.

(d) Not Applicable.

(e) Not Applicable.

ITEM 6. CONTACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

None.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

Reference is made to the Issuer's Registration Statement on Form S-8 filed on April 29, 2004, incorporated herein by reference.

3

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

June 17, 2004

Date

/s/ Ernest Armstrong

Ernest Armstrong

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

